Navigation Links
Laureate Biopharma to Produce Biosimilar Product for Leading Generics Company
Date:7/25/2011

PRINCETON, N.J., July 25, 2011 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced that they have entered into a multi-year development and manufacturing agreement with a leading generic pharmaceutical company to produce a biosimilar product.  Laureate's services will include transfer of the manufacturing process to Laureate and cGMP manufacture of this product for clinical trials through 2013. The agreement includes a customer option for long-term commercial supply.  Laureate expects to supply the first batch of clinical product during the first half of 2012.  Terms of the manufacturing agreement were not disclosed.

"Biosimilars are the immediate growth engine of the generic industry and we are pleased to be working with one of the leading generic companies in the world on this product," said Michael A. Griffith, CEO of Laureate Biopharma. "Manufacture of biosimilars is one natural extension of Laureate's existing portfolio of contract manufacturing services and represents a key strategic step for the company."  

About Biosimilars

Biosimilars are subsequent versions of recombinant therapeutic innovator products manufactured and sold by a different corporate sponsor following expiry of patent exclusivity for the innovator product.  With many innovator biopharmaceutical products going off patent in the next 5-10 years, there is an industry-wide effort to develop corresponding biosimilars. The U.S. FDA was given the authority to approve biosimilars within the Patient Protection and Affordable Care Act of 2010, following similar approvals in the European Union.  

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.LBioS.com.

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367, or info@LBioS.com or visit www.LBioS.com.


'/>"/>
SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Laureates Electronic Submission Gateway Approved
2. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
3. Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
4. Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals Antibody Therapeutic
5. Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research
6. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
7. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
8. Thomson Reuters Predicts Nobel Laureates
9. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
10. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
11. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/19/2017)... , Jan. 18, 2017 The ... Food and Drug Administration (FDA) for its release ... and population health decision makers can proactively share ... products as well as emerging therapies awaiting FDA ... mirrors consensus recommendations that AMCP developed during two ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
(Date:1/20/2017)... ... ... Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey ... Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes you. ... of my mind for years, but actually doing it might have been a while in ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
(Date:1/19/2017)... ... 2017 , ... Next week after January 20th, the fear for many is ... circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis at ... public servants were suppose to prioritize. Interviews provided below. , Among those ...
(Date:1/19/2017)... Delray Beach, Florida (PRWEB) , ... January 19, 2017 , ... ... Kolker J.D., LCSW, announced that the name of their drug rehab center in Delray ... is time we recognize that not only stars such as Philip Seymour Hoffman and ...
Breaking Medicine News(10 mins):